Search results
Kids With Skin Diseases Face Stigma, Reduced Quality of Life
Medscape· 1 day agoMost children with chronic skin diseases — such as acne, alopecia, eczema, psoriasis, and vitiligo —...
Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition...
Rome Sentinel· 5 days agoAdalimumab-aaty is also available from Celltrion USA under the brand name YUFLYMA®, which launched in July 2023 and is available at a 5% discount to the current WAC list price of HUMIRA. Adalimumab-aaty ...
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
Morningstar· 7 days agoEntered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027[1]Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials ...
Biodexa Pharmaceuticals (LON:MTPH) Share Price Passes Above 50 Day Moving Average of $18.00
ETF DAILY NEWS· 9 hours agoBiodexa Pharmaceuticals Plc (LON:MTPH – Get Free Report) shares passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of GBX 18 ($0.23) and ...
Japan's Takeda Pharma to restructure after annual profit slump
Reuters via Yahoo News· 5 days agoTOKYO (Reuters) -Japan's Takeda Pharmaceutical announced a restructuring on Thursday after annual...
Surprising Health Conditions Our Favorite Celebs Struggle With
Cheapism via AOL· 6 days agoBruce Glikas/Getty Images CC Kim Kardashian-West Condition: Psoriasis With so much of her career...
5 Best Undervalued Stocks To Buy In May 2024
Forbes· 5 days agoResearching undervalued stocks? We examined stocks to identify the top undervalued stocks in May 2024. Dive into the results here.
CTCL Global Care Collaborative Pioneers Consensus for Improving Diagnosis and Care in Cutaneous...
FOX 23 News Albany· 3 hours agoKyowa Kirin, Inc. a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced the publication of a patient-focused global consensus statement – 'Time to Act: A Global Patient-Focused Consensus ...
Brokers Offer Predictions for AnaptysBio, Inc.’s Q1 2025 Earnings (NASDAQ:ANAB)
ETF DAILY NEWS· 8 hours agoAnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Investment analysts at Wedbush issued their Q1 2025 earnings per share estimates for AnaptysBio in a research report issued on Thursday, May 9th ...
Microneedle Magic: New Alopecia Treatment Can Reverse Hair Loss
SciTechDaily· 5 days agoResearchers at MIT, Brigham and Women’s Hospital, and Harvard Medical School have developed a...